Company intelligence / Profile preview

MexBrain

Ownership: Private
Development stage: Other

Overview

MexBrain’s lead product MEX-CD1—a novel superchelating polymer used in conjunction with standard dialysis machines—has entered pilot clinical trials in Europe. The two main ongoing studies are evaluating safety and performance for the removal of free copper in Wilson’s Disease and free iron in acute on chronic liver failure. Both trials are currently recruiting patients[1][6].

Therapeutic areas: NephrologyRare DiseasesGastroenterology
Modalities: Medical devicePolymer-based therapy (superchelating polymer)Dialysis adjunct
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on MexBrain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MexBrain.

Explore the full profile